





Patent  
111411-02

patent, publication or other information referred to therein is material or considered to be material (37 CFR 1.97(h)), or even qualifies as "prior art" under 35 USC 102 with respect to this invention unless specifically designated by Applicant as such.

#### FILING PROVISION

This IDS is believed to be timely and is submitted under 37 CFR 1.97(b)(3) before the mailing of a first Office Action on the merits. However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c).

#### PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:

No fees are required with this filing under 37 CFR 1.97(b)(3), however, if applicant is incorrect in this regard or if the filing is accepted under 37 CFR 1.97(c), the Commissioner is hereby authorized to charge any fees required by the filing of these papers to Procopio's Deposit Account No. 50-2075.

Dated: \_\_\_\_\_

31 Aug 2004

Respectfully submitted,

By: \_\_\_\_\_

Harris F. Brotman  
Reg. No. 35,461

Procopio, Cory, Hargreaves & Savitch LLP  
530 B Street, Suite 2100  
San Diego, California 92101  
(619) 238-1900

111411-02

10/717,845

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## APPLICANT:

Ruth A. Gjeret, et al.

## FILING DATE:

November 19, 2003

## GROUP:

1653

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Publication Date/ Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code			
	AA	6,054,467	04-25-2000	Gjeret	
	AB	5,747,469	05-05-1998	Roth et al.	
	AC	2002/0193325 A1	12-19-2002	Depinho	
	AD	2002/0077313 A1	06-20-2002	Clayman	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	AE	BALINT, et al., Activation and activities of the p53 tumour suppressor protein .Br J Cancer. 85(12):1813-23 (2001)	
	AF	BEN-YEDIDIA, et al., Effect of Pre-Existing Carrier Immunity on the Efficacy of Synthetic Influenza Vaccine, Immunology Letters 64: 9-15 (1998)	
	AG	DE STANCHINA, et al., E1A signaling to p53 involves the p19(ARF) tumor suppressor; Genes Dev. 12(15):2434-42 (1998)	
	AH	DENG, et al., Recombinant Adenovirus-Mediated p14(ARF) Overexpression Sensitizes Human Breast Cancer Cells to Cisplatin, Biochem Biophys Res Commun. 296(4):792-8 (2002)	
	AI	EAVES-PYLES, et al., Salmonella Flagellin-Dependent Proinflammatory Responses are Localized to the Conserved Amino and Carboxyl Regions of the Protein, The Journal of Immunology 167:7009-7016 (2001)	
	AJ	ELLIOTT, et al., E2F-1 up-Regulates c-Myc and p14(ARF) and Induces Apoptosis in Colon Cancer Cells, Clin Cancer Res. 7(11):3590-7 (2001)	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Please initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. Thank you.

<sup>1</sup>Applicant is to place a check mark here if English language translation is attached.

FORM PTO-1449  LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 111411-02	<b>SERIAL NO.</b> 10/717,845
	<b>APPLICANT:</b> Ruth A. Gjerset, et al.	
	<b>FILING DATE:</b> November 19, 2003	<b>GROUP:</b> 1653

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	AK	GAO, et al. The exogenous wild-type p14ARF gene induces growth arrest and promotes radiosensitivity in human lung cancer cell lines, J Cancer Res Clin Oncol. 127(6):359-67 (2001)	
	AL	GJERSET, et al., Sensitization of tumors to chemotherapy through gene therapy, Adv Exp Med Biol 465:273-91 (2000)	
	AM	GJERSET, et al., Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 14:275-85 (1995)	
	AN	GONDI, et al., Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene. 22(38):5967-75 (2003)	
	AO	HARRIES, et al., Comparison of bicistronic retroviral vectors containing internal ribosome entry sites (IRES) using expression of human interleukin-12 (IL-12) as a readout. J Gene Med. 2(4):243-9 (2000)	
	AP	HEMMATI, et al., Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis, Oncogene 21(20):3149-61 (2002)	
	AQ	HUANG, et al., Enhanced Tumor Suppression by a P14ARF/p53 Bicistronic Adenovirus Through Increased p53 Protein Translation and Stability, Cancer Research 63:3646-3653 (2003)	
	AR	ITOSHIMA, et al., Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 down-regulation. Clin Cancer Res. 6(7):2851-9 (2000)	
	AS	KAMIJO, et al., Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2, Proc Natl Acad Sci U S A. 95: 8292-7 (1998)	
	AT	KATAYOSE, et.al., Cytotoxic effects of adenovirus-mediated p53 protein expression in normal and tumor mammary epithelial cells., Clin. Cancer Res. 1(8): 889-897 (1995)	
	AU	KIM, et al., Construction of a Bifunctional mRNA in the Mouse by Using the Internal Ribosomal Entry Site of the Encephalomyocarditis Virus, Molecular and Cellular Biology 12(8):3636-3643 (1992)	
	AV	LU, et al., Expression of p14ARF overcomes tumor resistance to p53, Cancer Res. 62: 1305-10. (2002)	

<b>EXAMINER:</b>	<b>DATE CONSIDERED:</b>
EXAMINER: Please initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. Thank you. <sup>1</sup> Applicant is to place a check mark here if English language translation is attached.	

<b>FORM PTO-1449</b>  <b>LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 111411-02	<b>SERIAL NO.</b> 10/717,845
	<b>APPLICANT:</b> Ruth A. Gjerset, et al.	
	<b>FILING DATE:</b> November 19, 2003	<b>GROUP:</b> 1653

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	AV	MCDERMOTT, et al., High-Affinity Interaction Between Gram-Negative Flagellin and a Cell Surface Polypeptide Results in Human Monocyte Activation, Infection and Immunity 68(10):5525-5529 (2000)	
	AW	MOORE, et al., Cooperativity of p19ARF, Mdm2, and p53 in Murine Tumorigenesis, Oncogene. 22(49):7831-7. (2003)	
	AX	MORGAN, et al., Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy Nucleic Acids Res. 20(6):1293-9. (1992)	
	AY	NEWTON, et al., Immune Response to Cholera Toxin Epitope Inserted in Salmonella Flagellin, Science 244:70-72 (1989)	
	AZ	REED, et al., The Salmonella Typhimurium Flagellar Basal Body Protein FliE is Required for Flagellin Production and to Induce a Proinflammatory Response in Epithelial Cells, The Journal of Biological Chemistry 277(15):13346-13353 (2002)	
	BA	SAADATMANDI, et al., Growth suppression by a p14(ARF) Exon 1beta Adenovirus in Human Tumor Cell Lines of Varying p53 and Rb Status.Cancer Gene Ther. 9(10):830-9. (2002)	
	BB	SAADATMANDI, et al., p53 Gene Therapy. In: J. R. Bertino (ed.) Encyclopedia of Cancer, second edition, Vol. 3. San Diego: Academic Press pp. 425-432 (2002)	
	BC	SHARPLESS, et al., The INK4a/ARF Locus and Melanoma. L.Oncogene. 22(20):3092-8. (2003)	
	BD	TANGO, et al., Adenovirus-Mediated p14ARF Gene Transfer Cooperates with Ad5CMV-p53 to Induce Apoptosis in Human Cancer Cells, Hum Gene Ther. 13: 1373-82. (2002)	
	BE	TSUCHIYAMA, et al., Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma.Cancer Gene Ther. 10(4):260-9. (2003)	
	BF	TSUJI, et al., p53-independent apoptosis is induced by the p19ARF tumor suppressor. Biochem Biophys Res Commun. 295(3):621-9. (2002)	
	BG	VERMA, et al., Induction of a Cellular Immune Response to a Defined T-Cell Epitope as an Insert in the Flagellin of a Live Vaccine Strain of Salmonella, Vaccine 13(3):235-244 (1995)	

<b>EXAMINER:</b>	<b>DATE CONSIDERED:</b>
EXAMINER: Please initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. Thank you. <sup>1</sup> Applicant is to place a check mark here if English language translation is attached.	

<b>FORM PTO-1449</b>  <b>LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 111411-02	<b>SERIAL NO.</b> 10/717,845
	<b>APPLICANT:</b> Ruth A. Gjerset, et al.	
	<b>FILING DATE:</b> November 19, 2003	<b>GROUP:</b> 1653

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	BH	VOORHOEVE PM, The tumor-suppressive functions of the human INK4A locus.Cancer Cell. 4(4):311-9. (2003)	
	BI	WAGNER, et al., Coupling of Adenovirus to Transferrin-Polylysine/DNA Complexes Greatly Enhances Receptor-Mediated Gene Delivery and Expression of Transfected Genes, Proc. Natl. Acad. Sci. USA 89:6099-6103 (1992)	
	BJ	WEBER, et al., Human P14ARF-Mediated Cell Cycle Arrest Strictly Depends on Intact p53 Signaling Pathways, Oncogene 21:3207-3212 (2002)	
	BK	YANG CT, Adenovirus-Mediated p14(ARF) Gene Transfer in Human Mesothelioma Cells, J Natl Cancer Inst. 92(8):636-41 (2000)	
	BL	YANG, et al., A Comparison Analysis of Anti-Tumor Efficacy of Adenoviral Gene Replacement Therapy (p14ARF and p16INK4A) in Human Mesothelioma Cells, Anticancer Res. 23(1A):33-8. (2003)	
	BM	YARBROUGH, et al., P16 and ARF: Crossroads of Tumorigenesis, Encyclopedia of Cancer 2 <sup>nd</sup> Edition 3:491-505 (2002)	
	BN	YOSHIMURA, et al., Expression of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene in the Mouse Lung After In Vivo Intratracheal Plasmid-Mediated Gene Transfer, Nucleic Acids Research 20(12):3233-3240 (1992)	
	BO	ZHANG et al., ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways, Cell. 92:725-34 (1998)	

<b>EXAMINER:</b>	<b>DATE CONSIDERED:</b>
EXAMINER: Please initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. Thank you. <sup>1</sup> Applicant is to place a check mark here if English language translation is attached.	